Stansberry Venture Value pick hints lead to an obesity drug company whose "only competition is itself"

What's the latest urgent pick promotion from Stansberry Venture Technology?

Yesterday’s Stansberry Digest carried the above teaser. It’s a small US-based chip company. Crucially, it actually makes its own chips within the US (rather than contracting out the production). Anyone any ideas? After years of membership, my first time posting, so forgive me if I’ve overstepped some protocols. I did have a look through the […]

Lashmet's "Opportunity #73" -- What's the recent IPO being teased by Stansberry Venture Value?

Sniffing out the teased Obesity stocks from Dave Lashmet's Stansberry Venture Technology

Checking into a teased anti-obesity drug that's not yet in the "mainstream headlines"

Dave Lashmet has been a biotech/medical analyst and sometimes a newsletter editor at Stansberry for a long time, and the latest iteration of his high-end newsletter is now called Stansberry Venture Technology (currently “on sale” for $2,500, no refunds)… and it’s now being promoted with a “cure for cancer” spiel, so we obviously all want […]

What's being touted when they guarantee, "This Stock Will Double in the Next 18 Months?"

Lots of readers have been sending questions our way about Porter Stansberry’s new high-cost Stansberry Venture Value newsletter, which is his attempt to build a service that essentially recommends small cap value stocks for long-term compounding value. An admirable goal, and I guess we’ll start to learn in the coming year or two how it’s […]

Monthly small-cap investing newsletter that aims to have a “venture capital” investing mindset, looking for high-risk opportunities for dramatic gains, primarily in tech or biotech. Listed as “Very Speculative” portfolio.